1.The Incidence of Gastroesophageal Reflux: Laryngeal Mask Airway vs Endotracheal Tube.
Dong Kyu CHO ; Young Pyo CHEONG ; Tai Yo KIM ; Jin Hee KIM ; Suck Chei CHOI ; Yong Ho NAH
Korean Journal of Anesthesiology 1997;32(3):377-383
BACKGROUND: There were several studies for the incidence of gastroesophageal reflux associated with the laryngeal mask airway(LMA), but the results of those studies were much different from one another. The authors of this study measured the intraesophageal pH at 5cm above lower esophageal sphincter(LES) to compare the incidence of gastroesophageal reflux associated with the LMA and the endotracheal tube(ETT) in positive pressure ventilated patients during long surgical procedures. METHOD: Ninety patients scheduled for elective orthopedic surgery with a standardized general anesthetic technique were randomly allocated to receive either a LMA(n=49) or a ETT(n=41) for airway management. The esophageal manometry was carried out for the exclusion of esophageal motility disorders and a probe with a pH electrode was passed nasally into the esophagus and positioned at 5 cm above LES one day before the operation. After that, recordings of pH for the diagnosis of gastroesophageal reflux disorder and for the detection of reflux episodes during and immediate after anesthesia were performed. RESULTS: There was no significant difference in the incidence of reflux(pH< or =4) between groups; only two patients in LMA and three patients in ETT had reflux episodes in the removal or arousal phase. All of them had experiences such as a coughing or straining during those phases. There was no clinical evidence of aspiration of gastric contents in either group. CONCLUSION: In comparison with ETT, use of LMA does not appear to result in increased incidence of reflux in positive pressure ventilated patients during long surgical procedures.
Airway Management
;
Anesthesia
;
Arousal
;
Cough
;
Diagnosis
;
Electrodes
;
Esophageal Motility Disorders
;
Esophagus
;
Gastroesophageal Reflux*
;
Humans
;
Hydrogen-Ion Concentration
;
Incidence*
;
Laryngeal Masks*
;
Manometry
;
Orthopedics
2.A Case of Intraventricular Oligodendroglioma Associated with Arterio-Venous Malformation.
Joong Whan NAH ; Hyung Dong KIM ; Sung Bo SHIM ; Yung Chul OK ; Kyu Woong LEE ; Jung Rye KIM ; Hyo Sook PARK
Journal of Korean Neurosurgical Society 1977;6(2):579-586
Bailey and Cushing described the oligodendroglioma firstly in 1926. The oligodendroglioma is rare tumor and involves the ventricular system in 7% to 10% of all cases. The authors present a case of intraventricular oligodendroglioma associated with arterio venous malformations in a 34 year old male who had the history of visual disturbance and mental deterioration, for one month. The diagnosis was confirmed by operation and autopsy.
Adult
;
Autopsy
;
Diagnosis
;
Humans
;
Male
;
Oligodendroglioma*
3.Frequency and Related Factors of Masked Hypertension at a Worksite in Korea.
Sang Kyu KIM ; Jun Ho BAE ; Dung Young NAH ; Dong Wook LEE ; Tae Yoon HWANG ; Kyeong Soo LEE
Journal of Preventive Medicine and Public Health 2011;44(3):131-139
OBJECTIVES: Masked hypertension is associated with metabolic risks and increased risk of cardiovascular disease. The purpose of this study was to identify the frequency of and risk factors of masked hypertension in Korean workers. METHODS: The study was conducted among 121 employees at a hotel in Gyeongju, Korea, from December 2008 to February 2009. We measured blood pressure (BP) both in the clinic and using 24-hour ambulatory BP monitors for all subjects. Hypertension was defined independently by both methods, and subjects were classified into four groups: true normotension, masked hypertension, white coat hypertension, and sustained hypertension. RESULTS: The frequency of masked hypertension in our study group was 25.6%. Compared with true normotension, the factors related to masked hypertension were male gender (odds ratio [OR], 10.7; 95% confidence interval [CI], 1.41 to 81.09), aging one year (OR, 0.88; 95% CI, 0.78 to 0.99), clinic BP 120-129/80-84 mmHg (OR, 8.42; 95% CI, 1.51 to 46.82), clinic BP 130-139 / 85-89 mmHg (OR, 12.14; 95% CI, 1.80 to 81.85), smoking (OR, 5.51; 95% CI, 1.15 to 26.54), and increase of total cholesterol 1 mg / dL (OR, 1.05; 95% CI, 1.02 to 1.08). In males only, these factors were clinic BP 120-129 / 80-84 mmHg (OR, 15.07; 95% CI, 1.55 to 146.19), clinic BP 130-139 / 85-89 mmHg (OR, 17.16; 95% CI, 1.56 to 189.45), smoking (OR, 11.61; 95% CI, 1.52 to 88.62), and increase of total cholesterol 1 mg/dL (OR, 1.05; 95% CI, 1.01 to 1.09). CONCLUSIONS: The frequency of masked hypertension was high in our study sample. Detection and management of masked hypertension, a known strong predictor of cardiovascular risk, could improve prognosis for at-risk populations.
Adult
;
Age Factors
;
Blood Pressure
;
Female
;
Health Behavior
;
Humans
;
Hypertension/*ethnology
;
Lipids/blood
;
Male
;
Middle Aged
;
Occupational Diseases/ethnology
;
Occupational Health/statistics & numerical data
;
Prevalence
;
Republic of Korea/epidemiology
;
Risk Factors
;
Sex Factors
;
Smoking/adverse effects/ethnology
;
Socioeconomic Factors
;
Stress, Psychological/complications/ethnology
;
Workplace/psychology/statistics & numerical data
4.A case of aural tuberculosis extended to the skull base and cervical vertebrae.
Yang Sun CHO ; Joo Hyun PARK ; Kwan PARK ; Dong Kyu NAH
Korean Journal of Otolaryngology - Head and Neck Surgery 2000;43(3):335-339
We experienced a case of primary middle ear tuberculosis extended to skull base and cervical spines. There were many reports of middle ear tuberculosis in korea, but no case of tuberculosis extended to the skull base has been reported. The patient underwent mastoidectomy for the diagnosis and the pathologic report was compatible with tuberculosis. We checked serially computed tomography and magnetic resonance image during 18 months of anti-tuberculosis chemotherapy and could find the gradual improvements of the infiltrating destructive skull base lesion.
Cervical Vertebrae*
;
Diagnosis
;
Drug Therapy
;
Ear, Middle
;
Female
;
Humans
;
Korea
;
Skull Base*
;
Skull*
;
Spine
;
Tuberculosis*
5.Serosurveillance for Japanese encephalitis, Akabane, and Aino viruses for Thoroughbred horses in Korea..
Dong Kun YANG ; Byoung han KIM ; Chang Hee KWEON ; Jin Ju NAH ; Hyun Joo KIM ; Kyung Woo LEE ; Young Jin YANG ; Kyu Whan MUN
Journal of Veterinary Science 2008;9(4):381-385
Recent global warming trends may have a significant impact on vector-borne viral diseases, possibly affecting vector population dynamics and disease transmission. This study measured levels of hemagglutination-inhibition (HI) antibodies against Japanese encephalitis virus (JEV) and neutralizing antibodies against Akabane virus (AKAV) and Aino virus (AINV) for Thoroughbred horses in Korea. Blood samples were collected from 989 racehorses in several provinces, between October 2005 and March 2007. Sera were tested using either an HI assay or a virus neutralization test. Approximately half (49.7%; 492/989) of the horses tested were antibody-positive for JEV. The HI titer against JEV was significantly correlated with racehorse age (p < 0.05). Horses with an HI antibody titer of 1: 160 or higher accounted for 3.9% of the animals tested, indicating that vectors transmitting arthropod- borne viruses bit relatively few horses. In contrast, 3.8% (19/497) and 19.5% (97/497) of horse sera collected in March 2007 were positive against AKAV and AINV, respectively. The presence of antibodies against AKAV and AINV may indicate the multiplication of AKAV and AINV in these horses.
Aging
;
Animals
;
Encephalitis Virus, Japanese/*isolation & purification
;
Hemagglutination Inhibition Tests/veterinary
;
Horse Diseases/blood/*epidemiology
;
Horses
;
Korea/epidemiology
;
Orthobunyavirus/*isolation & purification
;
Seroepidemiologic Studies
6.Endoscopic and Endosonographic Features of Histologically Proven Gastric Ectopic Pancreasby Endoscopic Resection
Ho-Sung LEE ; Dong Hyun KIM ; Seon-Young PARK ; Sunmin KIM ; Gwang Taek KIM ; Eunae CHO ; Jae Hyun YOON ; Chang Hwan PARK ; Hyun Soo KIM ; Sung Kyu CHOI ; Nah Ihm KIM ; Jong Sun REW
The Korean Journal of Gastroenterology 2020;76(1):9-16
Background/Aims:
Distinguishing gastric ectopic pancreas (GEP) from malignant tumors is relatively difficult. This study evaluated the endosonography findings of pathologically proven GEP.
Methods:
Thirty-one patients diagnosed with GEP based on a histopathological analysis from January 2004 to July 2018 were enrolled in this study. All patients underwent EUS and an endoscopic resection.
Results:
Seventeen patients were female, and the median age was 41.1 years (range, 14-74). The lesions were localized most commonly in the antrum. The mean size of the GEP was 10.6 mm (range, 7-15). Superficial type lesions, lesions with heterogeneous echogenicity, mixed pattern lesions, and lesions with indistinct borders were commonly observed on EUS. Calcification, anechoic duct-like structures, and thickening of the muscularis propria were observed in some patients. Endoscopic mucosal resection (41.9%) and endoscopic submucosal dissection (58.1%) were performed. The mean procedure time was 22.5 minutes. Complete resection was achieved for 71% of patients. No statistically significant results between the endosonography findings and complete resection rates were obtained. The mean follow-up esophagogastroduodenoscopy duration was 4.5 months. None of the patients presented with residual lesions on subsequent endoscopy.
Conclusions
EUS can help identify the features of GEP. Careful observations of the EUS findings can avoid unnecessary removal of GEP.
7.Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
Gil Chun PARK ; Shin HWANG ; Myoung Soo KIM ; Dong Hwan JUNG ; Gi Won SONG ; Kwang Woong LEE ; Jong Man KIM ; Jae Geun LEE ; Je Ho RYU ; Dong Lak CHOI ; Hee Jung WANG ; Bong Wan KIM ; Dong Sik KIM ; Yang Won NAH ; Young Kyoung YOU ; Koo Jeong KANG ; Hee Chul YU ; Yo Han PARK ; Kyung Jin LEE ; Yun Kyu KIM
Journal of Korean Medical Science 2020;35(6):36-
BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population.METHODS: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis.RESULTS: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ± 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence.CONCLUSION: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.
Antiviral Agents
;
Carcinoma, Hepatocellular
;
Cohort Studies
;
DNA
;
Follow-Up Studies
;
Half-Life
;
Hepatitis B Surface Antigens
;
Hepatitis B virus
;
Hepatitis B
;
Hepatitis
;
Humans
;
Immunoglobulins
;
Korea
;
Liver Transplantation
;
Liver
;
Organ Transplantation
;
Polymerase Chain Reaction
;
Recurrence
;
Transplants
8.Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
Gil Chun PARK ; Shin HWANG ; Myoung Soo KIM ; Dong Hwan JUNG ; Gi Won SONG ; Kwang Woong LEE ; Jong Man KIM ; Jae Geun LEE ; Je Ho RYU ; Dong Lak CHOI ; Hee Jung WANG ; Bong Wan KIM ; Dong Sik KIM ; Yang Won NAH ; Young Kyoung YOU ; Koo Jeong KANG ; Hee Chul YU ; Yo Han PARK ; Kyung Jin LEE ; Yun Kyu KIM
Journal of Korean Medical Science 2020;35(6):e36-
BACKGROUND:
Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population.
METHODS:
Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis.
RESULTS:
The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ± 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence.
CONCLUSION
Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.
9.Clinical experience with primary cardiac tumors.
Won Jae LEE ; Hyun Su JO ; Jang Won SON ; Jun Cheol YOON ; Chang Woo SON ; Kyu Hwan PARK ; Sang Hee LEE ; Geu Ru HONG ; Jong Sun PARK ; Dong Gu SHIN ; Young Jo KIM ; Dong Heon YANG ; Hun Sik PARK ; Chang Wook NAM ; Seung Ho HUR ; Ji Yong CHOI ; Kee Sik KIM ; Jun Ho BAE ; Deuk Young NAH ; Bong Ryeol LEE ; Byung Chun JUNG
Korean Journal of Medicine 2010;79(3):271-276
BACKGROUND/AIMS: In Korea, few studies have examined primary cardiac tumors, which have a reported incidence of 0.0017~0.19% in autopsy series. This study surveyed the status of primary cardiac tumors over the past 7 years in one region. METHODS: A retrospective review examined all patients with primary cardiac tumors, except for confirmed thrombus, using hospital medical records from 2000 to 2006 at six community hospitals. Identified cases undergoing biopsy and surgery were selected for the study. RESULTS: The operative mortality was 7.7%. Of the 71 patients (26 males) with identified primary cardiac tumors, 65 (91.5%) tumors were benign and 6 (8.5%) were malignant. The benign tumors were myxoma (78.9%), rhabdomyoma (4.2%), fibroelastoma (2.8%), fibroma (1.4%), and leiomyoma (1.4%). Two of the myxomas were present at multiple locations. The malignant tumors included sarcomas (67%) and lymphomas (33%). Most of the tumors were located in the left atrium (76%). The majority of patients presented with chest pain and dyspnea. During follow-up for an average of 26.8+/-21.3 months, all but one patient with benign tumors was alive; one myxoma patient died perioperatively (1.5%). Four of the patients with malignant tumors (67%) died. CONCLUSIONS: Cardiac myxomas and sarcomas were the most common primary benign and malignant tumors, respectively. Benign tumors had excellent postoperative survival rates, while malignant tumors had high mortality.
Autopsy
;
Biopsy
;
Chest Pain
;
Dyspnea
;
Fibroma
;
Follow-Up Studies
;
Heart Atria
;
Heart Neoplasms
;
Hospitals, Community
;
Humans
;
Incidence
;
Korea
;
Leiomyoma
;
Lymphoma
;
Medical Records
;
Myxoma
;
Retrospective Studies
;
Rhabdomyoma
;
Sarcoma
;
Survival Rate
;
Thrombosis
10.Functional Dyspepsia and Subgroups in Korea and Short Term Outcome of Therapeutic Trial of Cisapride: Multicenter Study.
Chung HUH ; Chang Heon YANG ; Jae Guen JANG ; Dong Ho LEE ; Kook Lae LEE ; Sang Young SEOL ; Youn Jae LEE ; Sok Won HAN ; Kyu Sung RIM ; Poong Lyul RHEE ; Won Chang SHIN ; Kwang Jae LEE ; Moon Kwan CHUNG ; Yong Ho NAH ; Jun Myeong KIM ; Do Young KIM ; Sun Young LEE ; Pum Soo KIM ; Don Haeng LEE ; Yong Woon SHIN ; Kye Sook KWON ; Jong Sun REW ; Hyun Chul PARK ; Hwoon Yong JUNG ; Young Il MIN ; Sang In LEE ; Myung Gyu CHOI ; Kyu Wan CHOI ; Na Young KIM ; Seon Hee LIM ; Kye Heui LEE ; Sung Kook KIM ; Yong Hwan CHOI ; Chi Wook SONG ; Heu Rang KIM ; Chang Young YIM ; Jyung Dong BAE ; Pil Joong KANG ; Byung Min AHN ; Soo Heon PARK ; Hyun Yong JEONG ; Sei Jin YOUN ; Hyang Soon YEO ; Jeong Seop MOON ; Hyo Jin PARK ; Hak Yang KIM ; Sang Woo LEE ; Yong Chan LEE ; Moon Ho LEE ; Seong Ho CHOI ; Mi Hye JUNG ; Chan Sup SHIM ; Joon Seong LEE ; Young Woo KANG ; Jong Chul RHEE
Korean Journal of Gastrointestinal Motility 1998;4(1):1-12
BACKGROUND/AIMS: The aims of this study were to determine subgoups of functional dyspesia and to evaluate the short-term effect of cisapride in patients with functional dyspepsia in Korea. METHODS: 1025 patients, with a mean age of 42.6 years, with symptoms of functional dyspepsia, were recruited consecutively and upper gastrointestinal symptoms were investigated by interview in 41 hospitals in Korea. In an open, multicenter trial, 1025 patients received Smg of cisapride three times a day (TID) for at least .2 weeks for the treatment of symptoms of functional dyspepsia. When necessary, the dose of cisapride was increased to 10mg TID and the duration of therapy was extended to 4 weeks. RESULTS: The most frequently reported symptoms of functional dyspepsia were epigastric discomfort or fullness (85%), bloating (70%), belching (53%), early satiety (52%) and epigastric pain (46%) retrospectively. Subgroups of functional dyspepsia were as follows; dysmotility-like 73.5%, ulcer-like 39.7%, reflux-like 13.0%, and unspecified dyspepsia 14.0%. However, 33.2% of subjects with functional dyspepsia could be classified into more than one subgroup. Upper gastrointestinal symptoms were decreased to average 50.3% (range; 42.2 to 59.2%) after 2 weeks of cisapride treatment and to 25% (19.2 to 29.9%) after 4 weeks. cisapride therapy resulted in good or excellent improvement in 59.0% of the patients after two weeks, in 75% of patients after 4 weeks. Adverse events were occurred in 52 patients (5.8% of all patients), most commonly, loose stools or diarrhea (3.5%), abdominal pain (1.1%), and dizziness (0.3%). The majority of adverse events was mild and transient in nature and led to premature discontinuation of treatment in 4 patients. CONCLUSIONS: Although the majorities of patients with functional dyspepsia have dysmotility like symptoms in Korea, there is such overlap among the dyspepsia subgroups. Most patients responded well to a short therapeutic trial with cisapride without significant side effects.
Abdominal Pain
;
Cisapride*
;
Diarrhea
;
Dizziness
;
Dyspepsia*
;
Eructation
;
Humans
;
Korea*
;
Retrospective Studies